The Next Agonist
Scenesse is a medicine. It is not a tan.
If you searched Scenesse hoping for a legal tan, the answer is no. Scenesse is an approved medicine for a rare disease in which light causes pain. It is not a cosmetic. It is not a vial. It is not Melanotan II with a better name.
What the approvals actually say
Scenesse is the brand name of afamelanotide, a melanocortin-1 receptor agonist. The European Commission granted a marketing authorisation for it on 22 December 2014, for erythropoietic protoporphyria. (EMA EPAR.) The FDA’s 2019 label indicates it to increase pain-free light exposure in adults with a history of phototoxic reactions from that same disease. (Prescribing information, revised October 2019.) Canada followed in 2026; that date is on the regulatory file.
The label is the lock. The endpoint in the trials was time in light without pain, in people whose skin burns in minutes because of a rare metabolic disorder. It was not hours of cosmetic darkness in healthy skin, and it was not skin cancer prevented. The prevention-claim file is where that misreading is taken apart.
It is also not a product a person inserts at home. The U.S. label says a healthcare professional who has completed the manufacturer’s training administers the implant. That sentence is here so the object is clear. It is not instructions.
Why you still cannot have it for a tan
The molecule cleared a regulator. The indication did not widen to the use the gray market wants. Getting from “treats a rare light-pain disease” to “darkens healthy skin, safely, for anyone” is a trials-and-payer problem, not a chemistry problem. That argument is the middle-ground essay. This page exists so the query “Scenesse tan” lands on the refusal before it lands on the economics.
Afamelanotide is the developed form of Melanotan I, the linear peptide from the Arizona program. Melanotan II — the cyclic peptide in the unlabeled vials — was the sibling that was not developed into a medicine. (One number, two fates.) Sharing a laboratory is not sharing a supply chain. A clinic implant with a named manufacturer is not a vial nobody tested.
Clinuvel is studying the same molecule in other diseases, including vitiligo. A repigmentation trial in people who have lost pigment is not a tanning indication either. That misreading is the one the beachhead file already draws. The readout itself gets a page when the result is public, not before.
Hope that a tested photoprotective medicine eventually reaches ordinary skin is this site’s labeled opinion. Scenesse, today, is not that medicine. It is a rare-disease implant. Anything sold as the tan Scenesse couldn’t be is the cautionary tale.
Common questions
Can I get Scenesse to tan?
No. Scenesse (afamelanotide) is approved to increase pain-free light exposure in adults with erythropoietic protoporphyria, a rare disease in which light causes severe pain. It is a clinic-administered implant, not a cosmetic, and it is not sold for tanning in healthy people.
Is Scenesse the same as Melanotan?
No. Scenesse is the approved medicine developed from Melanotan I. Gray-market products sold as Melanotan are almost always Melanotan II, an unapproved peptide with no manufacturer accountability. Sharing a history is not sharing a product.
Is Scenesse FDA approved?
Yes, for one use. The FDA approved Scenesse in 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. The European Commission authorised it on 22 December 2014 for the same rare disease. Neither approval is a licence to tan.